118 related articles for article (PubMed ID: 12063085)
1. RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: a c-Fos study at the spinal level.
Le Guen S; Noble F; Fournié-Zaluski MC; Roques BP; Besson JM; Buritova J
Eur J Pharmacol; 2002 Apr; 441(3):141-50. PubMed ID: 12063085
[TBL] [Abstract][Full Text] [Related]
2. Further evidence for the interaction of mu- and delta-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S). A spinal c-Fos protein study in the rat under carrageenin inflammation.
Le Guen S; Catheline G; Fournié-Zaluski MC; Roques BP; Besson JM; Buritova J
Brain Res; 2003 Mar; 967(1-2):106-12. PubMed ID: 12650971
[TBL] [Abstract][Full Text] [Related]
3. Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA receptor antagonist: a c-Fos study in the rat spinal cord.
Buritova J; Le Guen S; Fournié-Zaluski MC; Roques BP; Besson JM
Eur J Pain; 2003; 7(3):241-9. PubMed ID: 12725847
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
[TBL] [Abstract][Full Text] [Related]
5. Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
Noble F; Turcaud S; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1992 Nov; 223(1):83-9. PubMed ID: 1478260
[TBL] [Abstract][Full Text] [Related]
6. Effects of opioids and non-opioids on c-Fos-like immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation.
Abbadie C; Honoré P; Fournié-Zaluski MC; Roques BP; Besson JM
Eur J Pharmacol; 1994 Jun; 258(3):215-27. PubMed ID: 8088356
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management.
Nieto MM; Wilson J; Walker J; Benavides J; Fournié-Zaluski MC; Roques BP; Noble F
Neuropharmacology; 2001 Sep; 41(4):496-506. PubMed ID: 11543770
[TBL] [Abstract][Full Text] [Related]
8. When is the maximal effect of pre-administered systemic morphine on carrageenin evoked spinal c-Fos expression in the rat?
Honoré P; Chapman V; Buritova J; Besson JM
Brain Res; 1995 Dec; 705(1-2):91-6. PubMed ID: 8821738
[TBL] [Abstract][Full Text] [Related]
9. Intraplantar morphine depresses spinal c-Fos expression induced by carrageenin inflammation but not by noxious heat.
Honoré P; Buritova J; Besson JM
Br J Pharmacol; 1996 Jun; 118(3):671-80. PubMed ID: 8762093
[TBL] [Abstract][Full Text] [Related]
10. The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist.
Le Guen S; Honoré P; Catheline G; Fournié-Zaluski MC; Roques BP; Besson JM
Brain Res; 1999 Jul; 834(1-2):200-6. PubMed ID: 10407116
[TBL] [Abstract][Full Text] [Related]
11. Development of tolerance to the antinociceptive effect of systemic morphine at the lumbar spinal cord level: a c-Fos study in the rat.
Le Guen S; Catheline G; Besson JM
Brain Res; 1998 Nov; 813(1):128-38. PubMed ID: 9824685
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
Maldonado R; Valverde O; Turcaud S; Fournié-Zaluski MC; Roques BP
Pain; 1994 Jul; 58(1):77-83. PubMed ID: 7970841
[TBL] [Abstract][Full Text] [Related]
14. Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats.
Honoré P; Catheline G; Le Guen S; Besson JM
Pain; 1997 May; 71(1):99-108. PubMed ID: 9200179
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat.
Chapman V; Honoré P; Buritova J; Besson JM
Neuroscience; 1995 Aug; 67(3):731-9. PubMed ID: 7675199
[TBL] [Abstract][Full Text] [Related]
16. Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration.
Boudinot E; Morin-Surun M; Foutz AS; Fournié-Zaluski M; Roques BP; Denavit-Saubié M
Pain; 2001 Feb; 90(1-2):7-13. PubMed ID: 11166965
[TBL] [Abstract][Full Text] [Related]
17. Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.
Noble F; Coric P; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1992 Nov; 223(1):91-6. PubMed ID: 1478261
[TBL] [Abstract][Full Text] [Related]
18. Effects of NMDA receptor antagonists on morphine tolerance: a c-Fos study in the lumbar spinal cord of the rat.
Le Guen S; Catheline G; Besson JM
Eur J Pharmacol; 1999 May; 373(1):1-11. PubMed ID: 10408246
[TBL] [Abstract][Full Text] [Related]
19. The contribution of NMDA receptor activation to spinal c-Fos expression in a model of inflammatory pain.
Chapman V; Honoré P; Buritova J; Besson JM
Br J Pharmacol; 1995 Sep; 116(1):1628-34. PubMed ID: 8564229
[TBL] [Abstract][Full Text] [Related]
20. Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice.
Noble F; Fournié-Zaluski MC; Roques BP
Eur J Pharmacol; 1993 Jan; 230(2):139-49. PubMed ID: 8422896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
